Emergent Biosolutions Inc Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 7 Calls Today's Calls

Call Details Emergent Biosolutions Inc Earnings Conference Call (Q1 2008) Wed, May 7, 2008, 9:00 am Eastern Listen to the archived event audio About Emergent Biosolutions Inc (NYSE:EBS) Emergent BioSolutions, Inc., a biopharmaceutical company, together with its subsidiaries, develops, manufactures, and commercializes immunobiotics in the United States, the United Kingdom, and Vietnam. The company operates in two segments, Biodefense and Commercial. The Biodefense segment offers products for use against biological agents that are potential weapons of bioterrorism and biowarfare; and BioThrax, a vaccine for the prevention of anthrax infection. Its product candidates include Anthrax Immune Globulin therapeutic for the treatment of post-symptomatic anthrax infection; Next Generation anthrax vaccine; recombinant Botulinum vaccine, a prophylactic vaccine for illness caused by botulinum toxin; and Botulinum immune globulin to protect from the effects of botulinum toxin. The commercial segment develops products for use against infectious diseases. Its product candidates include Typhoid vaccine, a single-dose drinkable vaccine; and Group B streptococcus vaccine, a product in for administration to women of childbearing age for protection of the fetus and newborn babies. In addition, this segment offers Hepatitis B therapeutic vaccine, for the treatment of chronic carriers of hepatitis B infection; and Chlamydia vaccines, a product for administration to adolescents to prevent illness caused by strains of Chlamydia trachomatis. The company has license, co-development, and collaboration agreement with Sanofi Pasteur, S.A. to develop Neisseria meningitis B vaccine candidate; and the United Kingdom Health Protection Agency to develop a human Botulinum immune globulin candidate. Emergent BioSolutions, formerly known as BioPort Corporation, was founded in 1998 and is based in Rockville, Maryland. More Info: Quote | Profile | Reports | Research | Insider | Financials | Analyst Ratings